Ascendis Pharma A/S ASND.OQ, ASND.O is expected to show a fall in quarterly revenue when it reports results on May 1 for the period ending March 31 2025
The Hellerup Denmark-based company is expected to report a 1.3% decrease in revenue to €94.644 million from €95.89 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
LSEG's mean analyst estimate for Ascendis Pharma A/S is for a loss of €1.47 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 16.3% in the last three months.
Wall Street's median 12-month price target for Ascendis Pharma A/S is $200.00, above its last closing price of $164.88.
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.84 | -0.96 | -0.64 | Beat | 33.2 |
Sep. 30 2024 | -1.76 | -1.74 | -1.72 | Beat | 1.2 |
Jun. 30 2024 | -1.34 | -1.38 | -1.91 | Missed | -38.1 |
Mar. 31 2024 | -1.46 | -1.50 | -2.30 | Missed | -53.1 |
Dec. 31 2023 | -1.98 | -2.03 | -1.54 | Beat | 24 |
Sep. 30 2023 | -2.32 | -2.38 | -2.88 | Missed | -21.1 |
Jun. 30 2023 | -2.57 | -2.59 | -2.16 | Beat | 16.6 |
Mar. 31 2023 | -2.65 | -2.66 | -1.98 | Beat | 25.6 |
This summary was machine generated April 29 at 20:35 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。